Former Schrödinger exec launches RA Capital-backed startup for AI drug discovery

Ryan Cross

Senior Science Correspondent

Superluminal Medicines, a startup claiming that it can use artificial intelligence to shrink the development of preclinical drug candidates from years to a matter of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Former Schrödinger exec launches RA Capital-backed startup for AI drug discovery

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

For­mer Schrödinger ex­ec launch­es RA Cap­i­tal-backed start­up for AI drug dis­cov­ery

Senior Science Correspondent

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Former Schrödinger exec launches RA Capital-backed startup for AI drug discovery